降钙素原免疫分析在临床决策点附近的一致性评估
结果发现各方法分析一致性尚可,但相对于KRYPTOR,ARCHITECT i2000、MINI VIDAS和cobas e 411分别有21%、31%和16%的样本被分入不同的解释类别。研究支持PCT方法需要 harmonization,机构在引入PCT前应独立评估其检测方法。
要点
- 四种PCT免疫分析在临床决策点附近存在样本分类差异。
- 相对于KRYPTOR,MINI VIDAS正偏倚,ARCHITECT i2000和cobas e 411负偏倚。
- 机构在将PCT纳入临床实践前应独立评估其检测方法。
核心结论
- 所有方法显示合理的分析一致性,但在临床决策点附近许多样本被不同方法分入不同解释类别,支持PCT方法需要 harmonization。
主要发现
- MINI VIDAS相对于KRYPTOR呈正偏倚(斜率=1.188,R=0.9873)。
- ARCHITECT i2000和cobas e 411相对于KRYPTOR呈负偏倚(斜率=0.806,R=0.8864;斜率=0.795,R=0.8974)。
- 相对于KRYPTOR,ARCHITECT i2000使21%的样本被分入不同解释类别。
- 相对于KRYPTOR,MINI VIDAS使31%的样本被分入不同解释类别。
- 相对于KRYPTOR,cobas e 411使16%的样本被分入不同解释类别。
关键数值与推荐
- 常用临床决策点为0.10、0.25和0.50 μg/L。
临床怎么用
- 机构应独立评估其PCT检测方法与 predicate 方法的一致性,并在将PCT纳入临床实践前考虑对结果解释的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Procalcitonin (PCT) is a biomarker for systemic bacterial infections and may aid in decision making for antimicrobial stewardship. Numerous PCT assays are available on common clinical immunoassay platforms. However, questions remain about the harmonization of these assays and whether the same clinical decision points may be used with all methods. Methods Thirty-seven remnant patient serum samples were analyzed across four different PCT assays: Abbott ARCHITECT i2000, bioMérieux MINI VIDAS, Roche Elecsys cobas e 411, and BRAHMS KRYPTOR. Regression analysis was performed, and correlation was assessed at common clinical decision points for antimicrobial therapy: 0.10, 0.25, and 0.50 μg/L. Results Data showed a positive bias of the MINI VIDAS compared to the KRYPTOR (slope=1.188, R=0.9873) and negative biases of both the ARCHITECT i2000 and cobas e 411 compared to the KRYPTOR (slope=0.806, R=0.8864, and slope=0.795, R=0.8974, respectively). A comparison of results at commonly used clinical decision points for antimicrobial stewardship showed that, relative to the KRYPTOR, 21% of samples would be classified into different interpretive categories by the ARCHITECT i2000 method, 31% of samples would be classified differently by the MINI VIDAS method, and 16% of samples would be classified differently by the cobas e 411 method. Conclusions All methods showed reasonable analytical agreement; however, an analysis of result interpretation at clinical decision points showed that many samples were differentially categorized (e.g. shifted by one interpretive category) by the methods. Overall, our findings support a need for harmonization of PCT methods. Until then, institutions should independently evaluate their PCT assays against predicate methods and consider the impact on result interpretation prior to incorporating PCT into clinical practice.
引用
- Chambliss AB, Hayden J, Colby JM, et al. Evaluation of procalcitonin immunoassay concordance near clinical decision points. Clin Chem Lab Med. 2019. PMID: 30763263. doi:10.1515/cclm-2018-1362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。